| Author: | Barry Werth | ISBN: | 9781439126813 |
| Publisher: | Simon & Schuster | Publication: | August 20, 2013 |
| Imprint: | Simon & Schuster | Language: | English |
| Author: | Barry Werth |
| ISBN: | 9781439126813 |
| Publisher: | Simon & Schuster |
| Publication: | August 20, 2013 |
| Imprint: | Simon & Schuster |
| Language: | English |
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS.
You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS.
You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.
